基于DCE-MRI的影像组学列线图术前鉴别混合型肝细胞-胆管癌与肿块型肝内胆管癌
研究纳入训练队列151例(cHCC-CC 45例、IMCC 106例)和验证队列65例(cHCC-CC 19例、IMCC 46例),基于DCE-MRI提取影像组学特征构建列线图,联合甲胎蛋白、背景肝病(肝硬化或慢性肝炎)及影像组学标签,训练队列AUC为0.945、验证队列为0.897,优于单独影像组学标签或临床模型(p<0.05)。
要点
- 基于DCE-MRI的影像组学列线图在训练队列AUC 0.945、验证队列AUC 0.897,优于单独影像组学标签或临床模型。
- 列线图整合甲胎蛋白、背景肝病(肝硬化或慢性肝炎)及影像组学标签,用于术前鉴别cHCC-CC与IMCC。
- 影像组学标签由11个DCE-MRI特征经LASSO算法筛选构建。
核心结论
- 基于DCE-MRI的影像组学列线图可能为术前鉴别cHCC-CC与IMCC提供有效且无创的工具,有助于指导治疗策略。
研究设计与样本
- 研究纳入训练队列151例(cHCC-CC 45例、IMCC 106例)和验证队列65例(cHCC-CC 19例、IMCC 46例),分析临床特征和MR表现,从DCE-MR图像提取影像组学特征,采用LASSO算法构建影像组学标签,通过单因素和多因素分析筛选显著临床放射学变量并构建临床模型,再将影像组学标签与显著临床放射学变量纳入多因素逻辑回归构建影像组学列线图,用ROC曲线和AUC评估性能。
诊断标准与关键数值
- 列线图整合甲胎蛋白、背景肝病(肝硬化或慢性肝炎)及影像组学标签,训练队列AUC为0.945、验证队列AUC为0.897;影像组学标签训练队列AUC为0.848、验证队列AUC为0.792;临床模型训练队列AUC为0.856、验证队列AUC为0.809;列线图优于单独影像组学标签和临床模型(p<0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To establish a radiomics nomogram based on dynamic contrast-enhanced (DCE) MR images to preoperatively differentiate combined hepatocellular-cholangiocarcinoma (cHCC-CC) from mass-forming intrahepatic cholangiocarcinoma (IMCC).
METHODS: A total of 151 training cohort patients (45 cHCC-CC and 106 IMCC) and 65 validation cohort patients (19 cHCC-CC and 46 IMCC) were enrolled. Findings of clinical characteristics and MR features were analyzed. Radiomics features were extracted from the DCE-MR images. A radiomics signature was built based on radiomics features by the least absolute shrinkage and selection operator algorithm. Univariate and multivariate analyses were used to identify the significant clinicoradiological variables and construct a clinical model. The radiomics signature and significant clinicoradiological variables were then incorporated into the radiomics nomogram by multivariate logistic regression analysis. Performance of the radiomics nomogram, radiomics signature, and clinical model was assessed by receiver operating characteristic and area under the curve (AUC) was compared.
RESULTS: Eleven radiomics features were selected to develop the radiomics signature. The radiomics nomogram integrating the alpha fetoprotein, background liver disease (cirrhosis or chronic hepatitis), and radiomics signature showed favorable calibration and discrimination performance with an AUC value of 0.945 in training cohort and 0.897 in validation cohort. The AUCs for the radiomics signature and clinical model were 0.848 and 0.856 in training cohort and 0.792 and 0.809 in validation cohort, respectively. The radiomics nomogram outperformed both the radiomics signature and clinical model alone (p < 0.05).
CONCLUSION: The radiomics nomogram based on DCE-MRI may provide an effective and noninvasive tool to differentiate cHCC-CC from IMCC, which could help guide treatment strategies.
KEY POINTS: • The radiomics signature based on dynamic contrast-enhanced magnetic resonance imaging is useful to preoperatively differentiate cHCC-CC from IMCC. • The radiomics nomogram showed the best performance in both training and validation cohorts for differentiating cHCC-CC from IMCC.
引用
- Zhou, Zhou, Zhang, et al. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma. Eur Radiol. 2022. PMID: 35128572. doi:10.1007/s00330-022-08548-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。